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Abstract: Non-canonical amino acids (ncAAs) with dual 
stereocenters at the α and β positions are valuable precursors to 
natural products and therapeutics. Despite the potential applications 
of such bioactive β-branched ncAAs, their availability is limited due to 
the inefficiency of the multi-step methods used to prepare them. Here 
we report a stereoselective biocatalytic synthesis of β-branched 
tryptophan analogs using an engineered variant of Pyrococcus 
furiosus tryptophan synthase (PfTrpB), PfTrpB7E6. PfTrpB7E6 is the first 
biocatalyst to synthesize bulky β-branched tryptophan analogs in a 
single step, with demonstrated access to 27 ncAAs. The molecular 
basis for the efficient catalysis and broad substrate tolerance of 
PfTrpB7E6 was explored through X-ray crystallography and UV-visible 
light spectroscopy, which revealed that a combination of active-site 
and remote mutations increase the abundance and persistence of a 
key reactive intermediate. PfTrpB7E6 provides an operationally simple 
and environmentally benign platform for preparation of β-branched 
tryptophan building blocks. 
Amino acids are nature’s premier synthetic building blocks for 
bioactive molecules. Alongside the standard proteinogenic amino 
acids are diverse non-canonical amino acids (ncAAs) that are 
structurally similar but are not ribosomally incorporated into 
proteins. Due to the presence of functional groups that confer 
novel chemical and biological properties,[1] ncAAs can be found in 
natural products and 12% of the 200 top-grossing 
pharmaceuticals.[2,3] Of interest are β-branched ncAAs, which 
possess a chiral center at the β-position in addition to the standard 
chirality at the α-position of an amino acid (Figure 1a). The two 
adjacent stereocenters impose conformational constraints that 
affect the biochemical properties of both the amino acids 
themselves and the molecules they compose.[4–7] These 
properties make β-branched ncAAs frequent components of 
useful natural products, biochemical probes, and therapeutics 
(Figure 1b).[8–13] Despite their broad utility, most β-branched 
ncAAs are not readily available due to the challenge of forming 
two adjacent stereocenters while tolerating the reactive functional 
groups present in amino acids.[14–18] For example, traditional 
organic synthesis of (2S, 3S)-β-methyltryptophan (β-MeTrp) 
requires multiple steps that incorporate protecting groups, 
hazardous reagents, and expensive metal catalysts.[19,20] To take 
full advantage of these bioactive molecules, an improved 
methodology is needed to synthesize β-branched ncAAs. 
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Figure 1. Representative β-branched amino acids. (a) Examples of β-branched 
ncAAs. (b) Examples of products derived from β-branched tryptophan analogs 
(red). 
Enzymes offer an efficient and sustainable alternative to 
chemical synthesis and are routinely used to generate 
enantiopure amino acids from simple materials without the need 
for protecting groups.[21] Although several classes of enzymes 
have been employed in this pursuit, those using the pyridoxal 
phosphate cofactor (PLP, vitamin B6) are among the most 
prominent.[22] The most common biocatalytic route to an amino 
acid requires a fully assembled carbon skeleton and a PLP-
dependent transaminase which is used to set the 
stereochemistry. However, as with traditional organic 
methodologies, the enzymatic synthesis of β-branched ncAAs is 
often confounded by the presence of a second stereocenter. The 
capacity to incorporate biocatalytic C–C bond-forming steps en 
route to diverse β-branched ncAAs would therefore be a powerful 
synthetic tool.  
Few β-branched ncAA synthases have been reported, and 
even more rare are enzymes that produce branches larger than a 
methyl group. We previously engineered the β-subunit of the PLP-
dependent enzyme tryptophan synthase from the thermophilic 
archaeon Pyrococcus furiosus (PfTrpB) as a stand-alone ncAA 
synthase able to generate tryptophan (Trp) analogs from serine 
(Ser) and the corresponding substituted indole (Figure 2a).[23–25] 
Further engineering of PfTrpB for improved C–C bond formation 
with indole analogs and threonine (Thr) led to PfTrpB2B9 (eight 
mutations from wild-type PfTrpB), which exhibited a >1,000-fold 
improvement in (2S, 3S)-β-methyltryptophan (β-MeTrp) 
production relative to wild type (Figure 2b).[26,27] While the 
reactive amino-acrylate intermediate (E(A-A)) (Figure 3a) readily 
forms with Thr, mechanistic analysis showed that competing 
hydrolysis of (E(A-A)) resulted in abortive deamination that 
consumed the amino acid substrate (Figure 3b),[28,29] limiting the 
enzyme’s yield (typically < 50%) with a single equivalent of Thr. 
Further, PfTrpB2B9 accepted only Ser and Thr as substrates since 
larger β-alkyl substrates were unable to efficiently form E(A-A). 
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Figure 2. Synthesis of Trp and Trp analogs by PfTrpB. 
To surmount these challenges, we sought to identify 
mutations that would facilitate formation of E(A-A) with the more 
challenging (2S, 3R)-β-ethylserine (β-EtSer) and (2S, 3R)-β-
propylserine (β-PrSer) substrates while simultaneously 
decreasing E(A-A) hydrolysis (Figure 2c). The latter is essential, 
as increasingly bulky alkyl chains are thought to hinder 
nucleophilic attack. Increased E(A-A) persistence will allow more 
time for the intrinsically slower addition reaction to occur while 
reducing the amount of starting material lost to competing 
hydrolysis (Figure 3b).  
We chose PfTrpB2B9 as our engineering starting point to 
increase production of β-EtTrp. While an active catalyst with Thr, 
PfTrpB2B9 was sluggish with β-EtSer (80 total turnovers, TTN) and 
gave too little signal for high-throughput screening.[23] We 
speculated that active-site mutations would promote the formation 
of E(A-A) with larger, sterically demanding β-substituents and 
used a structure-guided approach to improve activity with β-
EtSer. Modeling β-EtSer into the PfTrpB2B9 active site as E(A-A) 
(PDB: 5VM5)[30] suggested a steric clash with L161 (Figure 4a). 
Hypothesizing that this constraint could be reduced by mutating 
L161 to a residue with a smaller side chain (Figure 4b), we 
expressed and assayed variants PfTrpB2B9 L161V, L161A, and 
L161G. We found that L161V and L161A increased the TTN 14-
fold and 10-fold, respectively, whereas L161G decreased activity 
by a factor of 2.6 (Figure 4c). As our long-term interest is to 
produce a catalyst that accommodates a wider range of β-alkyl 
chains, we selected PfTrpB2B9 L161A as the parent enzyme for 
directed evolution, with the rationale that the smaller sidechain of 
alanine would minimize steric clashes with bulkier substrates. 
We then introduced random mutations into the PfTrpB2B9 
L161A gene and screened for enhanced β-EtTrp synthesis (Table 
1) at 290 nm under saturating substrate conditions.[23] Screening 
made use of starting materials containing a mixture of 
diastereomers, however only the (2S,3R) diastereomer 
underwent a productive reaction. High-throughput screening of 
352 variants yielded PfTrpB0E3 (L91P), which displayed a 43-fold 
increase in TTN for β-EtTrp (Figure 4d). PfTrpB0E3 was then used 
as the parent for a second round of random mutagenesis, yielding 
variant PfTrpB8C8 (V173E), which improved β-EtTrp yields by 54-
fold relative to PfTrpB2B9. At this juncture, a third round of random 
mutagenesis failed to yield further improvements after screening 
880 variants. Although the accumulated mutations increased 
activity, we speculated that further improvements were hindered 
by deleterious mutations that reduced enzyme stability.[31] We 
therefore recombined mutations in TrpB8C8, allowing a 50% 
chance for each residue to retain the mutation or revert to wild 
type. Recombination included all residues except those which 
were crucial for starting activity with Ser (T292S), Thr (F95L), and 
β-EtSer (L161A and L91P) (Table S1). Recombination also 
included F274L, which was previously identified as an activating 
mutation.[23] Recombined variants were assayed for β-EtTrp 
production at 290 nm, which revealed that I68V and T321A were 
non-essential, but that F274L was beneficial, yielding variant 
PfTrpB7E6. Though PfTrpB7E6 did not show improved stability 
(Table S2), recombination did enhance activity, with a 58-fold  
 
Figure 3. The putative catalytic cycle for PfTrpB synthesizing β-MeTrp. (a) 
Catalysis initiates as E(Ain) with the mobile COMM domain predominantly in the 
open conformation (blue). With the addition of Thr, the COMM domain 
undergoes rigid body motion, transitioning to a partially closed position through 
E(Aex1) (red) followed by full closure with formation of the reactive E(A-A) 
intermediate (green). E(A-A) is then attacked by indole and undergoes an 
addition reaction to form β-MeTrp. (b) E(A-A) may also undergo a kinetically 
competing hydrolysis reaction to generate α-keto acids, observable at 320 nm. 
This deamination reaction consumes an equivalent of the amino acid substrate. 
          
 
 
 
 
improvement relative to PfTrpB2B9 (Figure 4d). An additional 
round of recombination sampled other previously identified 
activating mutations (Q38R, M139L, N166D, S335N) and allowed 
for reversion of L91P. This process produced a variant (PfTrpB2G8, 
see Table 1) that lacked the L91P mutation and had only slightly 
lower activity than PfTrpB7E6. Although subsequent work showed 
that PfTrpB2G8 is also a proficient enzyme (vide infra), the parent 
PfTrpB7E6 was selected for mechanistic characterization as it is a 
comparatively simple catalyst with excellent activity and more 
amenable to crystallization. 
 
Figure 4. Engineering PfTrpB for β-EtTrp synthesis. (a) β-EtSer as E(A-A) 
(yellow) modeled in the PfTrpB2B9 (PDB: 5VM5, gray) active site. Spheres 
represent the Van der Waals radii and highlight a clash with L161 (green). (b) 
As in (a), but with the mutation L161A shown (purple). (c) β-EtTrp production by 
PfTrpB2B9 with L161V, L161A, or L161G mutations. (d) β-EtTrp production by 
engineered PfTrpB variants. Bars represent the average of all data points, with 
individual reactions shown as circles. At minimum, reactions were performed in 
duplicate. 
We sought to identify which newly evolved properties of 
PfTrpB enabled increased TTNs with challenging β-branched 
substrates. As described above, the activity and substrate scope 
of the parent enzyme, PfTrpB2B9, were limited by low steady-state 
population (abundance) and subsequent breakdown 
(persistence) of the reactive E(A-A) intermediate.[27] To assess 
the abundance of E(A-A), we capitalized on the intrinsic 
spectroscopic properties of the PLP cofactor to visualize the 
steady-state distribution of intermediates throughout the catalytic 
cycle (Figure 3a).[32] With the addition of β-EtSer to PfTrpB7E6, the 
internal aldimine peak (E(Ain), 412 nm) decreased and E(A-A) 
(350 nm) became the major species (Figure 5a). This is a notable 
change, as when β-EtSer was added to PfTrpB2B9, E(Aex1) 
accumulated and no E(A-A) was observed (Fig 5a). To assess 
the persistence of E(A-A), we assayed the deamination rate and 
coupling efficiency of PfTrpB7E6. In the presence of both Thr and 
β-EtSer, PfTrpB7E6 displayed up to a 4-fold decrease in the 
deamination reaction relative to PfTrpB2B9 (Table S3). We then 
probed the enzyme’s coupling efficiency under reaction 
conditions with high catalyst loading and equimolar substrate 
equivalents, where product formation is limited only by the 
consumption of starting material through the competing 
deamination reaction. We observed an increase in product 
formation from 5% with PfTrpB2B9 to 96% with PfTrpB7E6 when β-
EtSer was the substrate (Figure 5b). Collectively, these data 
indicate that increased product formation was achieved by 
incorporating mutations that facilitate the formation of E(A-A) and 
increase its lifetime in the active site.  
During directed evolution, PfTrpB was altered by the 
introduction of nine mutations. Although PfTrpB7E6 has only a 
single mutation in the active site (Figure S1), mutations governing 
enzyme activity are scattered throughout the protein.[23,33] Remote 
mutations may be affecting the enzyme’s conformational 
dynamics, which have been previously shown to be linked to the 
catalytic cycle of PfTrpB (Figure 3a).[30,33] In its resting state, 
PfTrpB binds PLP via the catalytic lysine (K82) as E(Ain) with the 
mobile communication (COMM) domain in a predominantly open 
conformation. Addition of an amino acid substrate induces 
formation of the external aldimine (E(Aex1)), which is 
accompanied by partial closure of the COMM domain. 
Dehydration to form the electrophilic E(A-A) species occurs when 
TrpB populates a fully closed conformation, where it remains until 
product is formed.[28,29] To examine the state of the PfTrpB7E6 
active site and its connection to the COMM domain 
conformational cycling, we determined the X-ray crystal 
structures of PfTrpB7E6 in the E(Ain) state as well as with β-EtSer 
bound in the active site as E(A-A).  
 
Figure 5. Directed evolution stabilizes E(A-A) and improves coupling efficiency. 
(a) The steady-state population of PfTrpB as determined by UV-visible light 
spectroscopy. In the absence of substrate, the predominant population of 
PfTrpB7E6 (black) is E(Ain). β-EtSer-bound PfTrpB2B9 (orange) accumulates 
E(Aex1) and PfTrpB7E6 (green) forms E(A-A). All spectra are normalized to the 
absorbance value of E(Ain) at 412 nm. (b) Variant coupling efficiency with β-
EtSer. Bars represent the average of all data points, with individual reactions 
shown as circles. At minimum, reactions were performed in duplicate. 
Earlier PfTrpB variants, including PfTrpB2B9, were nearly 
identical to wild-type PfTrpB (PDB: 5DVZ) in the open state. Here, 
the 2.26-Å structure of PfTrpB7E6 (PDB: 6CUV) shows distinct 
preorganization toward a more closed conformation. Specifically, 
 
Table 1. Engineering PfTrpB through directed evolution for improved β-
EtTrp production. Engineering began with PfTrpB2B9 (PfTrpB I16V, E17G, 
I68V, F95L, F274S, T292S, T321A, and V384A) with 80 TTN. All reactions 
were performed in at least duplicate with 0.1% catalyst loading for 24 hours 
at 75 °C.  
Variant Mutations  
Added 
Mutations 
Removed 
Average 
TTN 
[a]PfTrpB2B9 
L161A  
L161A N/A 800 
[b]PfTrpB0E3 L91P N/A 3400 
[b]PfTrpB8C8 V173E N/A 4300 
[c]PfTrpB7E6 F274L I68V, T321A 4600 
[c]PfTrpB2G8 M139L, N166D, S335N L91P 3800 
[a] Site-directed mutagenesis. [b] Random mutagenesis. [c] Recombination. 
 
          
 
 
 
 
in half of the protomers, the COMM domain has shifted into a 
distinct partially-closed conformation that was previously 
associated with substrate binding (Figure 6a). While many 
residues may contribute to the stabilization of this state, we 
hypothesize that the mutation L91P destabilizes open states; this 
residue lies on an α-helix immediately prior to the COMM domain 
in the sequence and causes a kink in the helix that shifts the 
structure toward more closed states (Figure 6b).  
We next soaked PfTrpB7E6 with β-EtSer and obtained a 1.75-
Å structure with β-EtSer bound as E(A-A) in two protomers (PDB: 
6CUZ). As expected, the COMM domain underwent rigid-body 
motion to the closed conformation (Figure 6a) where the steric 
complementarity between the longer β-alkyl chain and L161A 
becomes apparent. Notably, the L161A mutation does not appear 
to induce significant alterations elsewhere in the active site 
(Figure 6c). When indole is modeled into the active site, there is 
space to accommodate even longer β-branched substituents as 
well as a range of indole nucleophiles (Figure 6d). 
 
Figure 6. Substrate binding and conformational changes in PfTrpB. (a) The 
COMM domain of PfTrpB undergoes rigid body motion that is linked to the 
catalytic cycle. In the absence of substrate, wild-type PfTrpB (PDB: 5DVZ, gray) 
is in the open conformation, while PfTrpB7E6 (PDB: 6CUV, green) assumes a 
partially closed conformation. When β-EtSer is bound to PfTrpB7E6 as E(A-A) 
(PDB: 6CUV, orange), the COMM domain undergoes a rigid body shift to a 
closed conformation. (b) The mutation L91P introduces a kink in the α-helix 
adjacent to the COMM domain. (c) β-EtSer bound to PfTrpB7E6 as E(A-A) is 
shown with Fo-Fc map contoured at 2.0σ (green). The gamma carbon of the 
amino-acrylate is not well resolved. Hydrogen bonds are shown as red dashes. 
(d) Indole (yellow) modeled in the active site of PfTrpB7E6 with β-EtSer as E(A-
A). The green dash represents the bond-forming atoms in indole and β-EtSer.  
As our goal was to evolve a versatile β-branched ncAA 
synthase, we next explored the substrate scope of PfTrpB7E6. We 
hypothesized that, if improvements in activity came through 
increased stability of E(A-A), the same mutations should increase 
activity with multiple amino acid substrates. Indeed, we found that 
although we screened for β-EtTrp synthesis, the TTN for β-MeTrp 
and (2S, 3S)-β-propyltryptophan (β-PrTrp) synthesis were 
simultaneously improved 3.6-fold and 36-fold, respectively 
(Figure 7a). Consistent with our previous observations, directed 
evolution improved the enzyme’s coupling efficiency (Figure 7b) 
and amino-acrylate persistence (Figure 7c-d) with all three acid 
substrates. Next, we revisited our earlier hypothesis that the 
L161A mutation would be more beneficial than L161V by reducing 
steric clashes with larger substrates. We observed that although 
PfTrpB7E6 L161V is viable for synthesis of β-MeTrp and β-EtTrp, 
the TTN for β-PrTrp formation was reduced 5-fold (Figure S2a). 
In addition, PfTrpB7E6 retained the robust Trp activity that is the 
hallmark of the wild-type enzyme (Figure S2b), demonstrating 
that the L161A mutation was successful in accommodating 
bulkier substrates, allowing catalysis with four different amino acid 
substrates.  
 
Figure 7. PfTrpB engineering grants access to a range of β-branched 
tryptophan analogs. (a) TTN of PfTrpB for β-MeTrp (orange), β-EtTrp (blue), 
and β-PrTrp (green). (b) Variant coupling efficiency with Thr (orange), β-EtSer 
(blue), and β-PrSer (green). Bars represent the average of all data points, with 
individual reactions shown as circles. At minimum, reactions were performed in 
duplicate. (c) The steady-state population of PfTrpB with Thr as determined by 
UV-visible light spectroscopy. In the absence of substrate, the predominant 
population of PfTrpB7E6 (black) is E(Ain). With the addition of Thr to PfTrpB2B9 
(orange) has a mixed population of E(Aex1) and E(A-A), while PfTrpB7E6 (green) 
is predominantly E(A-A). (d) β-PrSer-bound PfTrpB2B9 (orange) remains as 
E(Ain) while PfTrpB7E6 (green) predominantly forms E(A-A). 
However, activity was not observed with all β-alkyl 
substrates and reactions with (2S)-β-isopropylserine (β-iPrSer) 
showed only trace activity. To understand why catalysis did not 
proceed with this bulkier sidechain, we soaked β-iPrSer into 
PfTrpB7E6 crystals and obtained a 1.77-Å structure (PDB: 6CUT), 
which shows the catalytically unreactive (2S, 3S) diastereomer of 
β-iPrSer bound as E(Aex1) (Figure S3). Though (2S, 3S)-β-iPrSer 
can form E(Aex1), dehydration across the Cα–Cβ bond requires a 
rotameric shift of the side chain that we hypothesize is hindered 
by steric interactions with an adjacent loop.[34] Further work is 
needed to understand whether the poor activity of PfTrpB7E6 with 
(2S, 3R)-β-iPrSer reflects inhibition by an isomeric analog, 
increased allylic strain of the amino-acrylate, or a combination of 
effects. 
In addition to acting on multiple amino acid substrates, we 
hypothesized that PfTrpB7E6 would retain the wild-type enzyme’s 
breadth of reactivity with indole analogs.[23–25] We performed 
analytical biotransformations with 11 representative nucleophiles 
with three β-branched amino acid substrates, yielding 27 
tryptophan analogs, 20 of which are previously unreported (Table 
2). Each reaction was analyzed by liquid-chromatography/mass 
spectrometry (LCMS) and TTN were calculated by comparing 
product and substrate absorption at the isosbestic wavelength 
(Table S4). Happily, we found that substituted indole analogs 
          
 
 
 
 
remained well-tolerated by PfTrpB7E6. Methyl substituents were 
accepted around the indole ring, though the enzyme 
demonstrated higher activity with fluoroindoles. We also observed 
activity with 5-chloroindole and Thr, a reaction that was 
undetectable for the parent enzyme, PfTrpB2B9. In addition, we 
have abolished the undesirable N-alkylation reaction that 
occurred with PfTrpB2B9 in the presence of 7-azaindole and 4-
fluorindole.[27] However, yields with N-nucleophilic substrates 
such as indazole remained low with β-branched substrates 
relative to their Ser counterparts. Importantly, PfTrpB7E6 can 
synthesize these ncAAs using only a single equivalent of the 
amino acid substrate, whereas PfTrpB2B9 had required 10 
equivalents. This is a testament to the value of improving the 
stability of the reactive E(A-A) intermediate in the reaction. 
 All product identities were confirmed by 1H- and 13C-NMR as 
well as high-resolution mass spectrometry from 100-μmol 
preparative reactions using two equivalents of electrophilic 
substrate. Reactions were conducted at 0.01 to 0.4 mol% catalyst 
loading, and we found that, under these conditions, PfTrpB7E6 
maintained robust activity: β-MeTrp with 6,600 TTN (88% yield), 
β-EtTrp with 6,200 TTN (82% yield), and β-PrTrp with 2,100 TTN 
(84% yield). We also used the recombination variant PfTrpB2G8 
(Table 1) to synthesize and characterize 27 tryptophan analogs 
on a preparative scale (Table S5). For future applications, 
reactions may be further optimized by tuning catalyst loading and 
increasing substrate equivalents (Table S6). In conjunction with 
the high expression levels of PfTrpB7E6 (~300 mg enzyme per L 
culture), a range of β-branched ncAAs are now accessible on a 
preparative scale. We have developed a new biocatalytic route to 
(2S, 3S)-tryptophan analogs using the engineered thermostable 
catalyst, PfTrpB7E6. Through directed evolution, we increased the 
abundance and persistence of the key E(A-A) intermediate by the 
introduction of active-site and remote mutations. In turn, PfTrpB7E6 
displays improved coupling efficiency with multiple β-branched 
amino acid substrates. 
This work significantly extends previous efforts to engineer 
PfTrpB enzymes, which have proven to be versatile and efficient 
catalysts for production of tryptophan analogs. 
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